Grifols (GIFLF) Long-Term Investments (2009 - 2025)
Grifols' (GIFLF) quarterly Long-Term Investments came in at $112.9 million in Q4 2025, up 53.14% on a YoY basis from $73.7 million in Q4 2024, and up 53.14% quarter-over-quarter from $73.7 million in Q4 2024.
Analysis
Grifols (GIFLF) Long-Term Investments (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Long-Term Investments for 17 consecutive years, with $112.9 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Investments rose 53.14% year-over-year to $112.9 million; the trailing twelve-month figure through Dec 2025 stood at $112.9 million (up 53.14% YoY), and the FY2025 full-year result was $109.6 million, up 1726.53% from the prior year.
- Long-Term Investments grew to $112.9 million in Q4 2025 per GIFLF's latest filing, from $73.7 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $1.8 billion in Q4 2021 and bottomed at $73.7 million in Q4 2024.
- Historically, Long-Term Investments has averaged $786.5 million across 5 years, with a median of $453.0 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments plunged 83.72% in 2024, then jumped 53.14% in 2025.
- Over 5 years, Long-Term Investments stood at $1.8 billion in 2021, then slipped by 13.39% to $1.5 billion in 2022, then plunged by 70.36% to $453.0 million in 2023, then slumped by 83.72% to $73.7 million in 2024, then surged by 53.14% to $112.9 million in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $112.9 million, $73.7 million, and $453.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 112.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 112.91 Mn |
| Dec 31, 2024 | 73.73 Mn |
| Dec 31, 2023 | 452.97 Mn |
| Dec 31, 2022 | 1.53 Bn |
| Dec 31, 2021 | 1.76 Bn |
| Dec 31, 2020 | 2.23 Bn |
| Sep 30, 2020 | 2.19 Bn |
| Mar 31, 2020 | 2.11 Bn |
| Dec 31, 2019 | 126.71 Mn |
| Sep 30, 2019 | 138.01 Mn |
| Mar 31, 2019 | 269.66 Mn |
| Dec 31, 2018 | 258.99 Mn |
| Sep 30, 2018 | 261.93 Mn |
| Jun 30, 2018 | 269.46 Mn |
| Mar 31, 2018 | 271.47 Mn |
| Dec 31, 2017 | 257.87 Mn |
| Jun 30, 2017 | 245.73 Mn |
| Dec 31, 2016 | 217.40 Mn |
| Sep 30, 2016 | 220.93 Mn |
| Jun 30, 2016 | 228.70 Mn |